D
DYN
Dyne Therapeutics, Inc.
19.81
+0.81+4.26%After Hours: 20.00 +0.19 +0.96%18:51 04/14 EDT
OPEN/PREV CLOSE19.15/19.00
TODAY RANGE18.89-19.99
VOL2.28M
MARKET CAP3.27B
52 WEEK RANGE7.01-25.00
AVG VOL (3M)2.14M
% TURNOVER1.38%
TURNOVER--
P/E (TTM)-5.7024
% RANGE5.79%
EPS(TTM)-3.4740
P/E(FORWARD)-6.6225
P/B3.361
BVPS5.89
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.07B
SHARES OUTSTANDING165.22M
NEXT EARNINGS05/06-05/11
FREE FLOAT155.16M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·04/06 00:22
A Look At Dyne Therapeutics (DYN) Valuation After Strong Recent Share Price Momentum
Simply Wall St·04/02 08:19
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders
TipRanks·04/02 02:02
Insider Scoop: Dyne Therapeutics Director Makes a Bold New Purchase
Seeking Alpha·03/19 18:37
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Simply Wall St·03/16 23:24
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)?
TipRanks·03/16 11:35
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)
Simply Wall St·03/14 18:36
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case
TipRanks·03/14 02:08
Top Dyne Therapeutics Insider Quietly Boosts Stake in Bold New Move
Reuters·03/13 20:47
Dyne Therapeutics Director Brian S. Posner Acquires Common Shares
Reuters·03/13 20:36
Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares
Simply Wall St·03/13 14:17
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data
Reuters·03/11 21:28
Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares
Same Industry
Name/Symbol
Change%
Price